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 CURRENTOPINION Hypoxia in atherosclerosis and inflammation
Elke Marscha, Judith C. Sluimera, and Mat J.A.P. Daemenb
Purpose of review
Hypoxia triggers various cellular processes, both in physiological and pathological conditions, and has
recently also been implicated in atherosclerosis. This review summarizes the recent evidence for the
presence and the role of hypoxia in atherosclerosis. Additionally, it will elucidate on hypoxic signaling,
which is interlinked with inflammatory signaling, and discuss recent advances in imaging of hypoxia in
atherosclerosis.
Recent findings
Hypoxia is present in atherosclerotic plaques in humans and animal models, and systemic hypoxia
promotes atherosclerosis. Hypoxia stimulates proatherosclerotic processes, like deficient lipid efflux,
inflammation, interference with macrophage polarization and glucose metabolism. However, the molecular
mechanism of hypoxia-mediated atherogenesis remains unclear.
Noninvasive imaging directly targeting plaque hypoxia has been applied in animal models of
atherosclerosis, but remains to be validated in humans. Meanwhile, the metabolic marker
18F-fluorodeoxyglucose, used to detect human atherosclerosis in vivo, may serve as an indirect marker of
plaque hypoxia due to enhanced glucose uptake in anaerobic metabolism.
Summary
Recent studies underscore the proatherogenic role of hypoxia in macrophage lipid and glucose
metabolism, inflammation and polarization. These studies provide new insights into the pathogenesis of
atherosclerosis and unravel novel therapeutic targets and new options for noninvasive imaging of human
atherosclerotic plaques.
Keywords
atherosclerosis, hypoxia, imaging, macrophages, metabolism
INTRODUCTION: EVIDENCE OF HYPOXIA
IN ATHEROSCLEROSIS – A HISTORICAL
VIEW
Low oxygen tension, hypoxia, is an important
stimulus of both pathological and physiological
processes including angiogenesis, inflammation,
metabolism and apoptosis. All of these processes
are implicated in atherogenesis. Arterial wall
hypoxia has been extensively studied using micro-
electrodes in vitro and in vivo in healthy arteries
and atherosclerosis injury models in rabbits [1–5].
More recently, Björnheden et al. [6,7] showed zones
of hypoxia in rabbit atherosclerotic plaques, using
the imidazole derivate 7-[40-(2-nitroimidazol-1-yl)-
butyl)-theophylline (NITP)], and suggested a
co-localization of hypoxia with foam cells (macro-
phages). NITP undergoes intracellular nitroreduc-
tion (mainly by cytochrome p450) [8], resulting in
reactive intermediates. In cells with a partial oxygen
pressure below 10 mmHg, these intermediates form
stable adducts with cellular thiol groups in proteins,
peptides and amino acids [9].
Using the imidazole derivate pimonidazole, we
recently conclusively demonstrated the presence of
hypoxia in human atherosclerotic plaques in vivo. As
for rabbit atherosclerosis, macrophages are the
major cell types in human plaques that display signs
of hypoxia, with co-existent expression of hypoxia-
inducible factor 1a (Hif-1a) and vascular endothelial
growth factor (VEGF). Furthermore, hypoxia corre-
lated with intra-plaque angiogenesis [10]. Auto-
radiography of the imidazole marker [18F]-EF5
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[2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluo
ropropyl)] was also able to detect hypoxia in athero-
sclerotic plaques in LDLR/ApoB100/100 and IGF-II/
LDLR/ApoB100/100 mice [11]. Murine plaque
hypoxia was also confirmed in LDLR/ mice in vivo
using pimonidazole and pimonidazole positivity
again co-localized with macrophages [12
&
]. On the
basis of these studies, the presence of hypoxia in
human and murine atherosclerotic plaques is nowa-
days widely accepted; however, the functional invol-
vement of hypoxia in atherogenesis remains unclear.
Cells respond to hypoxic conditions by adjusting
metabolism, angiogenesis, inflammation, migration,
endothelial dysfunction and cell survival signaling
[13,14
&
,15]. These processes mainly involve the tran-
scription factor Hif-1 [16]. Hif-1 is composed of a a
and b subunit, with Hif-1a being continuously
degraded under normoxic conditions, whereas
hypoxia increases its stability and transcriptional
activity [17]. In human atherosclerotic plaques, we
showed co-expression of the hypoxic marker pimo-
nidazole and Hif-1a, suggesting a role of Hif-1a in
atherosclerosis [10]. However, it should be noted that
Hif-1a can also be stabilized under normoxic con-
ditions and therefore does not exclusively represent
hypoxia. Atherosclerotic factors including reactive
oxygen species (ROS) [18], thrombin [19], lipopoly-
saccharide [20], oxidized LDL (oxLDL) [21], protein
kinase C and phosphatidylinositide 3-kinase path-
ways [22] have also been shown to promote Hif-1a
stabilization in normoxia.
In this review, we will summarize the recent
findings on a causal role for hypoxia-driven signal-
ing in atherogenesis. As macrophages present
the main hypoxic component of atherosclerotic
plaques, we will focus on oxygen deprivation-medi-
ated disturbances in macrophage functions, such as
lipid and glucose metabolism, polarization and
inflammatory signaling.
ATHEROGENESIS: HYPOXIA-DRIVEN?
Atherosclerotic vascular disease is the leading cause
of morbidity and mortality in the industrialized
world [23]. Evidence for a clinically relevant and
progressive role of hypoxia in atherosclerosis is pro-
vided by obstructive sleep apnea (OSA) patients.
OSA patients suffer from chronic intermittent cycles
of hypoxia and reoxygenation [chronic intermittent
hypoxia (CIH)] [24] and present with an increased
risk for atherosclerosis and subsequent cardiovas-
cular disease [25–30].
CIH is believed to be the major cause of OSA-
associated atherosclerotic cardiac events (reviewed
in [31]), in parts, by CIH-induced oxidative stress,
which is elevated in OSA patients [32]. Even though
local plaque hypoxia has not been shown in OSA
patients so far, CIH models suggest a proatherogenic
role of systemic hypoxia in atherosclerosis. Also,
CIH induced atherosclerosis in C57Bl6 mice fed a
high-cholesterol diet, whereas C57Bl6 mice sub-
jected to high-cholesterol diet alone did not show
lesion development. Exposure of ApoE/ mice to
CIH accelerated atherosclerosis progression on
high-cholesterol diet but also on normal chow
[33–36]. Conversely, early signs of atherosclerosis,
including arterial wall thickening and stiffness in
OSA patients, can be reversed by continuous
positive airway pressure therapy (CPAP) [37,38].
CPAP reverses upper airway narrowing by delivering
compressed air, making unobstructed breathing
possible and restoring hypopneas and apneas.
Additionally, hyperbaric oxygen treatment
(HBOT, 2.4–2.5 atm, 100% O2) reduced athero-
sclerosis in both rabbit and mouse models. It
increased antioxidant enzymes and attenuated
both lipid oxidation and the proinflammatory
immune response [39–41]. In humans, HBOT
improved atherosclerosis in patients with diabetic
feet and in a patient with atherosclerotic cerebral
infarction [42,43]. Unfirer et al. [44] proposed
that the advantageous effect of HBOT on regression
of atherosclerosis and diabetes mellitus might be
due to a reoxygenation-mediated restoration of
endothelial function. However, the mechanism
underlying the beneficial effect of systemic re-
oxygenation on atherosclerosis and the effect on
plaque hypoxia remains unclear. Moreover, the
direct link between HBOT and atherosclerosis
regression, as shown in animal models and case
reports, remains to be confirmed in large-scale
human atherosclerosis studies.
In conclusion, hypoxia is present in atheroscler-
otic plaques and systemic oxygen alterations in CIH
and HBOT suggest a proatherosclerotic effector role
of systemic hypoxia. However, whether this effect is
mediated by local changes in plaque hypoxia is
KEY POINTS
 Atherosclerotic plaque hypoxia is present
across species.
 Hypoxia stimulates atherosclerosis.
 Hypoxia and inflammation share similar pathways,
including NF-kB activation.
 Hypoxia alters macrophage lipid and glucose
metabolism, inflammation and polarization and vice
versa.
 Noninvasive plaque imaging may target hypoxia
directly using imidazole analogues or indirectly using
18F-FDG PET.
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unclear and the underlying molecular mechanism
remains obscure.
HYPOXIA AND INFLAMMATION SHARE
SIMILAR PATHWAYS: IS NF-kB THE KEY?
Oxygen demand, and thus hypoxia, is particularly
elevated at sites of inflammation, for example,
wounds or atherosclerotic lesions [45
&
]. In this
respect, it is not surprising that hypoxia and inflam-
matory responses share similar intracellular path-
ways, including metabolic alterations, macrophage
phenotype switching and oxidative stress signaling.
In this review, we will discuss the recent advances in
hypoxia and inflammation signaling in athero-
sclerosis.
Hypoxia has mainly been studied with respect to
lipid metabolism, as LDL modification and accumu-
lation in the vessel wall and foam cell formation
present critical steps in atherogenesis. Hypoxia
enhances LDL oxidation, promotes triglyceride syn-
thesis and loading of foam cells [46
&
,47], inhibits
cholesterol influx and enhances LDL affinity of
macrophages [48] (extensively reviewed in [49
&
]).
Along this line, foam cell formation could be
inhibited in vitro by Hif-1a RNA interference [50].
Mechanistically, the dyslipidemic effect of hypoxia
has been linked with LXR expression and down-
regulation of cholesterol efflux receptors, such as
ATP-binding cassette transporter (ABCA-1) [49
&
,51].
In fact, Hif-1a overexpression reduced cholesterol
efflux from macrophages, which was even further
decreased upon hypoxia [51]. A recent study now
showed that another inflammatory transcription
factor, nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-kB), was required for chole-
sterol efflux/uptake receptors ABCA-1 and SR-B1
protein expression in CIH-induced atherosclerosis.
Additionally, NF-kB subunit p50/ mice presented
with reduced hyperlipidemia and foam cell for-
mation in CIH-induced atherosclerosis [52
&
]. This
confirms earlier findings, where p50/ attenuated
atherosclerosis development in mice and reduced
oxLDL uptake by p50/ macrophages, also in the
absence of systemic hypoxia [53]. Another study
showed that the hypoxic effect on lipid clearance
was mediated by inhibition of lipoprotein lipase
(LpL) and that this effect was independent of NF-
kB [54
&
]. In addition to the NF-kB-mediated dyslipi-
demic effects, NF-kB contributed to macrophage
differentiation, recruitment and foam cell for-
mation [55], as well as endothelial dysfunction in
chronic intermittent hypoxia models [56
&
].
In conclusion, hypoxia and inflammation share
common signaling pathways, amongst others NF-kB
activation. In concert, hypoxia and inflammation
affect multiple processes, like lipid metabolism and
cholesterol efflux, endothelial dysfunction and
inflammation.
HYPOXIA ALTERS GLUCOSE
METABOLISM AND OXIDATIVE STRESS
SIGNALING AND VICE VERSA
Chronic inflammation is a feature of atherosclerosis
and mounting an inflammatory response is an
energy-intensive process. At sites of inflammation,
macrophages rapidly switch from a resting to an
activated state, resulting in increased cytokine
production, enhanced phagocytosis and antigen
presentation, all resulting in excessive ATP con-
sumption [57
&
]. This inflammatory switch has been
shown to be at least partially mediated by Hif-1a in
both normoxic and hypoxic conditions [58,59] and
is accompanied by a metabolic shift towards
glycolysis, a phenomenon known as the Warburg
effect. The Warburg effect describes the switch
from oxygen-dependent mitochondria-mediated
oxidative phosphorylation (OXPHOS) to glycolysis
in tumor cells and highly proliferative cells. This
switch can occur both in normoxic and hypoxic
conditions and thus involves both aerobic and
anaerobic glycolysis [60,61]. It is well established
that aerobic metabolism via OXPHOS produces
more ATP per glucose molecule (in fact 36 ATP)
than glycolysis. Yet, cancer and inflammatory cells
decide for a seemingly less efficient metabolism via
glycolysis, with only two ATP being produced per
glucose molecule. This discrepancy can be explained
by looking at metabolism as an interlinked network,
rather than pathways. During glycolysis, precursors
of amino acid synthesis and nucleotide anabolism
are generated, which are crucial for biomass
accumulation and proliferation [61]. If nutrients
are abundant, cells are hence easily capable of main-
taining homeostasis by relying purely on glycolysis,
both in inflammation and hypoxia.
Upon inflammation and hypoxia, T cells and
macrophages switch their metabolism towards gly-
colysis, with macrophages presenting with a more
proinflammatory M1-like phenotype [62–64]. In
fact, Folco et al. [65] recently demonstrated that
hypoxia rather than inflammation promotes glu-
cose uptake by macrophages in vitro. M2 macro-
phages were shown to maintain oxidative
phosphorylation for ATP production (reviewed in
[66
&
]). Also in rabbit atherosclerotic lesions, hypoxic
macrophages showed increased glucose consump-
tion and ATP depletion, suggesting the Warburg
effect in atherosclerosis. In vitro, hyperoxic re-
oxygenation of rabbit plaques could reverse ATP
depletion, whereas normoxic conditions could
Hypoxia in atherosclerosis and inflammation Marsch et al.
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not, suggesting that oxygen availability rather than
glucose concentration is the limiting factor in ATP
production within the plaques [67]. In turn,
increased glycolysis promotes lactate production
and acidification of the plaque environment. In fact,
elevated blood lactate has recently been associated
with increased carotid atherosclerotic wall thickness
in humans, although this was partially related
to insulin resistance [68]. As plaque and systemic
acidification are proatherogenic [69,70], enhanced
lactate due to increased glycolysis may contribute
to atherogenesis.
Apart from enhanced lactate production,
hypoxia results in increased ROS production by
a dysregulated mitochondrial respiratory chain
(reviewed in [71]). ROS are implicated in oxLDL
formation, endothelial activation, monocyte-
derived macrophage recruitment, activation and
death, vascular smooth muscle cell proliferation
and death, and matrix remodeling [72,73]. Mito-
chondria, which are majorly dependent on oxygen
during respiration, sense oxygen depletion and
subsequently release ROS into the cytosol. ROS in
turn stabilizes Hif-1a via various pathways, includ-
ing inhibition of prolyl hydroxylase-mediated Hif
hydroxylation (reviewed in [74]). Macrophages,
representing the largest hypoxic fraction in athero-
sclerosis [10], are also the main source of ROS and
oxidative stress in the plaque [75
&&
], suggesting a
link between hypoxia and ROS in plaque pro-
gression. In accordance, ROS inhibition by statins
has been shown to improve hypoxia-induced
endothelial dysfunction [76]. Also, OSA patients
present with elevated oxidative stress levels and





]. These data confirm a metabolic switch
towards glycolysis in atherosclerotic macrophages,
with subsequent lactate and ROS production con-
tributing to endothelial dysfunction and plaque
advancement. However, whether hypoxia promotes
this glycolytic shift, or whether hypoxia is secon-
dary to enhanced glycolysis and inflammation
in vivo, remains to be elucidated. On the basis of
the fact that even small mouse lesions present
hypoxic areas, we postulated that macrophage oxy-
gen demand rather than impaired oxygen diffusion
promotes hypoxia in macrophages in atherosclerotic
plaques [10]. This would suggest that plaque hypoxia
is secondary to a metabolic switch towards glycolysis






























FIGURE 1. Suggested model of plaque oxygen availability and metabolic effects on macrophages. Upon entering the arterial
wall, monocytes differentiate into macrophages, which in turn take up oxLDL and become activated. With increased
inflammation, cytokine and ROS production, as well as glucose and ATP demand, macrophage oxygen consumption exceeds
oxygen availability. Consequently, macrophages display signs of hypoxia, contributing to plaque progression, even though
oxygen diffusion rates from the lumen into the plaque remain constant (credit to Volker Zerbe, www.volker-zerbe.de). ROS,
reactive oxygen species.
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HYPOXIA ALTERS MACROPHAGE
POLARIZATION AND INFLAMMATION
As indicated, hypoxia can induce the glycolytic
switch and M1 macrophages show increased glyco-
lytic activity [64]. It has therefore been speculated
that hypoxia can promote proinflammatory M1
macrophage differentiation, thereby aggravating
atherogenesis. However, there is conflicting evi-
dence for a hypoxia-mediated M1 macrophage
phenotype switch. In vitro, macrophages display
M1 polarization upon hypoxia [81
&
] and Hif-1a
knockout macrophages present a M2 tumor-associ-
ated macrophage (TAM) marker profile [82]. How-
ever, in vivo, M2 TAMs accumulate in hypoxic tumor
regions and both M1 and M2 adipose tissue macro-
phages (ATMs) amass in distinct hypoxic adipose
tissue [81
&
,82]. These data suggest the presence of
an additional M2 macrophage trigger overriding
hypoxia in inflammatory tissue in vivo. In this
respect, lactate and pH, as well as growth factors
and necrotic debris, have been described for the
tumor environment [83], suggesting a secondary
effect of the Warburg effect and lactate production
on M2 polarization.
In atherosclerotic lesions, both M1 and M2
macrophage populations increased during plaque
progression towards unstable lesions in vivo, with
M1 macrophages localizing in rupture-prone areas
[84
&
]. Also, studies on tumor hypoxia and macro-
phage distribution show that mainly M2-like TAMs
are localized in hypoxic regions [85], supporting the
idea of an additional trigger towards M2-like macro-
phage marker expression overriding hypoxia. This is
not surprising, as the plaque and tumor environ-
ment are very heterogeneous and contain various
growth factors and inflammatory mediators. In this
respect, we suggest that atherosclerotic plaque
macrophages might resemble the tumor macro-
phages.
In conclusion, hypoxia seems to induce pro-
inflammatory responses in macrophages. However,
hypoxia is not sufficient in inducing macrophage
phenotype switching in vivo, as it is balanced by yet
unknown factors.
HYPOXIA AS A NONINVASIVE IMAGING
TOOL OF ATHEROSCLEROSIS
Knowing the proatherosclerotic role of hypoxia,
imaging of plaque hypoxia may become a relevant
and desirable prognostic and diagnostic tool for
atherosclerosis. Several imidazole analogs [18F]-EF5
[86], [18F]-HX4 (3-[18F]fluoro-2-[4-(2-nitro-1Himida
zol-1-yl)methyl)-1H-1,2,3,-triazol-1-yl]-propan-1-ol)
[87] and 18F-fluoromisonidazole ([18F]-MISO) [88
&&
]
have been positively tested in imaging of hypoxia in
tumors; however, they remain to be validated in
atherosclerosis imaging. Recently, hypoxic athero-
sclerotic areas in LDLR/ApoB100/100 mice were
successfully imaged ex vivo using [18F]-EF5 and
PET scan. [18F]-EF5 signal on autoradiography was
significantly higher in atherosclerotic plaques com-
pared to the normal arterial vessel wall and uptake
was independent of calcification and, surprisingly,
inflammatory state of the plaque [11]. Recent
studies and the above described metabolic shift in
plaque macrophages suggest that the metabolic
marker 18F-fluorodeoxyglucose (18F-FDG) can be
used as an indirect marker of hypoxia in vivo.
18F-FDG is a glucose analog PET tracer, which is
taken up particularly by highly proliferative and
glycolytically active cells and has hence also been
linked with inflammation. In-vitro data show that
glucose uptake in human macrophages is stimu-
lated to a greater extent by hypoxic conditions as
compared to inflammatory triggers [65], suggesting
that 18F-FDG uptake can be used to visualize plaque
hypoxia. In vivo, 18F-FDG positivity has been linked
with tumor inflammation and also atherosclerotic
plaques could be detected in oncology patients
[89–92]. However, there is conflicting evidence
for the effectiveness of 18F-FDG as a hypoxic marker.
Whereas 18F-FDG did not correlate well with
18F-MISO in sarcomas [93], 18F-FDG PET signal posi-
tivity correlated with hypoxia-mediated gene
expression in murine atherosclerosis, including
genes like Hif-1a and VEGF [94
&
]. Only a few human
atherosclerosis imaging studies have been per-
formed so far [95]. These correlate the 18F-FDG
uptake to macrophage presence in the plaque,
and symptomatic unstable plaques show greater
18F-FDG uptake compared to advanced plaques
[92,94
&
,96,97]. Thus, 18F-FDG represents an indirect
tool to measure hypoxia and inflammation in
atherosclerotic plaques and was recently success-
fully used to monitor decreases in human plaque
inflammation under atorvastatin, pioglitazone and
the HDL-raising compound dalcetrapib [98]. A com-
bination with imidazole-based hypoxia PET scan
markers and 18F-FDG may prove useful in diagnosis
of plaque phenotypes and plaque progression.
CONCLUSION
Recent studies have confirmed the presence of
hypoxia in atherosclerotic plaques and its co-local-
ization with macrophages. Systemic hypoxia sleep
apnea models and clinical studies reveal the pro-
atherosclerotic role of hypoxia and mechanistically
link hypoxia with impaired macrophage function.
Intracellular lipid accumulation and LDL oxidation
and macrophage glucose metabolism are induced,
Hypoxia in atherosclerosis and inflammation Marsch et al.
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resulting in ROS signaling, lactate production and
acceleration of disease.
From this evidence, we conclude that hypoxia
may well represent one of the main drivers
of atherosclerosis by interfering with macro-
phage function. Additionally, recent evidence
interlinks plaque hypoxia with macrophage meta-
bolic changes;however, a causal relationship remains
to be established.
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Stöger JL, Gijbels MJJ, Van der Velden S, et al. Distribution of macrophage
polarization markers in human atherosclerosis. Atherosclerosis 2012;
225:461–468.
The authors link the presence of M1 and M2 macrophage populations to different
areas within the plaque, while no clear association of specific populations with
plaque types is found.
85. Laoui D, Van Overmeire E, Movahedi K, et al. Mononuclear phagocyte
heterogeneity in cancer: different subsets and activation states reaching
out at the tumor site. Immunobiology 2011; 216:1192–1202.
86. Abramson Cancer Center of the University of Pennsylvania. Fluorine F18-EF5
and fludeoxyglucose F18 positron emission tomography in assessing hypoxia
and glycolysis in patients with stage I, stage II, or stage III non-small cell lung
cancer (Full Text View – ClinicalTrials.gov. Clinicaltrials.gov) 2012.
87. Van Loon J, Janssen MHM, Ollers M, et al. PET imaging of hypoxia using




Tachibana I, Nishimura Y, Shibata T, et al. A prospective clinical trial of tumor
hypoxia imaging with 18F-fluoromisonidazole positron emission tomography
and computed tomography (F-MISO PET/CT) before and during radiation
therapy. J Radiat Res 2013.
In this study, tumor hypoxia is successfully visualized with the hypoxic tracer
18F-MISO. Hypoxic tumor areas were found in all patients and could be reversed
after two weeks of fractionated radiation therapy.
89. Dunphy MPS, Freiman A, Larson SM, et al. Association of vascular
18F-FDG uptake with vascular calcification. J Nuclear Med 2005; 46:
1278–1284.
90. Tatsumi M, Cohade C, Nakamoto Y, et al. Fluorodeoxyglucose uptake in the
aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology
2003; 229:831–837.
91. Yun M, Yeh D, Araujo LI, et al. F-18 FDG uptake in the large arteries: a new
observation. Clin Nuclear Med 2001; 26:314–319.
92. Bural GG, Torigian DA, Chamroonrat W, et al. FDG-PET is an effective
imaging modality to detect and quantify age-related atherosclerosis in large
arteries. Eur J Nuclear Med Molec Imag 2008; 35:562–569.
93. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG
PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and
VEGF expression. Eur J Nuclear Med Molec Imag 2003; 30:695–704.
Hypoxia in atherosclerosis and inflammation Marsch et al.
0957-9672  2013 Wolters Kluwer Health | Lippincott Williams & Wilkins www.co-lipidology.com 399
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
94.
&
Hag AMF, Pedersen SF, Christoffersen C, et al. (18)F-FDG PET imaging of
murine atherosclerosis: association with gene expression of key molecular
markers. PloS One 2012; 7:e50908.
This study associates the uptake of the metabolic marker 18F-FDG with expres-
sion of key atherosclerosis markers, in particular VCAM, tissue factor (TF) and
CD68.
95. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on
atherosclerotic disease using novel noninvasive multimodality imaging (dal-
PLAQUE): a randomised clinical trial. Lancet 2011; 378:1547–1559.
96. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose
positron emission tomography imaging provides a noninvasive measure of
carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48:1818–
1824.
97. Kwee RM, Truijman MTB, Mess WH, et al. Potential of integrated [18F]
fluorodeoxyglucose positron-emission tomography/CT in identifying vulner-
able carotid plaques. Am J Neuroradiol 2011; 32:950–954.
98. Rosenbaum D, Millon A, Fayad ZA. Molecular imaging in atherosclerosis: FDG
PET. Current Atherosclerosis Reports 2012; 14:429–437.
Atherosclerosis: cell biology and lipoproteins
400 www.co-lipidology.com Volume 24  Number 5  October 2013
